SUTINAT 12.5MG

Sorafenat 200 mg Tablet may increase your risk of infections; consult your physician if you notice any symptoms of infection such as fever, sore throat, difficulty breathing, jaundice, unexplained bleeding, or bruising.
Your physician may recommend regular blood tests, as well as kidney and liver function tests to keep track of your health status.
Make sure to inform your doctor about your medical history and any medications you are taking to avoid any adverse effects.

Sutinat 12.5 Capsule is classified as an ‘antineoplastic agent’ and is utilized in the treatment of gastrointestinal stromal tumors (cancer affecting the stomach, bowel, or esophagus) in patients who do not respond to imatinib (another cancer treatment).
It is also indicated for renal carcinoma (kidney cancer) that has metastasized to other areas of the body and for advanced pancreatic neuroendocrine tumors (cancer affecting hormone-producing cells in the pancreas).

Sutinat 12.5 Capsule contains sunitinib, which works by slowing the proliferation of cancer cells through two mechanisms.
It disrupts the function of a protein that encourages cell division, thus reducing the production of cancer cells.
Additionally, it can block angiogenesis, the process by which blood supply is developed for cancer cells.
This action limits the nutrient supply to the cancer cells, ultimately leading to their death.

You should take this medication precisely as directed by your physician.
Common side effects of Sutinat 12.5 Capsule include difficulty in breathing, elevated blood pressure, severe fatigue, swelling due to fluid retention under the skin and around the eyes, and pain or irritation in the mouth.
Before your physician prescribes Sorafenat 200 mg Tablet, inform them if you have any heart conditions, high blood pressure, bleeding disorders, have undergone surgery, or have an electrolyte imbalance (such as abnormal levels of magnesium, calcium, or potassium in your blood).
Sorafenat 200 mg Tablet is contraindicated in individuals who are allergic to any of its components or have squamous cell lung cancer or are currently receiving carboplatin and paclitaxel.